

IN THE CLAIMS:

The following listing of claims will replace all prior versions and listings of the claims in this application:

Claims 1-13. (Canceled)

Claim 14. (Currently Amended): A composition for the treatment of asthma, the composition comprising:

a montelukast sodium component;

an antihistamine component selected from the group consisting of cetirizine, fexofenadine, and combinations thereof; and

a sympathomimetic bronchodilator component, wherein said sympathomimetic bronchodilator component is albuterol, wherein said albuterol includes an immediate release form and an extended release form, wherein said immediate release form is present in an amount substantially equal to said extended release form.

Claim 15. (Canceled)

Claims 16. (Withdrawn): A method for treating asthma comprising the steps of:

preparing a composition comprising:

a first receptor antagonist in the amount of between about 4.0 mg and about 20.0 mg;

a second receptor antagonist in the amount of between about 2.5 mg

and about 180.0 mg, said second receptor antagonist being different from said first receptor antagonist;

an adrenergic bronchodilator in the amount of between about 4.0 mg and about 8.0 mg; and

administering said composition to a patient.

Claim 17. (Withdrawn): The method of Claim 16, wherein said first receptor antagonist and said second receptor antagonist are selected from the group consisting of leukotriene receptor antagonists and histamine receptor antagonists.

Claim 18. (Withdrawn): The method of Claim 16, wherein said adrenergic bronchodilator is a β_2 -adrenergic bronchodilator.

Claims 19-22. (Canceled)

Claim 23. (Currently Amended): A composition for the treatment of asthma, the composition comprising:

- (a) a leukotriene receptor antagonist component;
- (b) a histamine receptor antagonist component selected from the group consisting of cetirizine hydrochloride, [[and]] fexofenadine, and combinations thereof; and
- (c) an adrenergic bronchodilator component, wherein said adrenergic bronchodilator component includes an immediate release form and an extended release form wherein, said immediate release form is present in an amount substantially equal to said extended release form.

Claim 24. (Currently Amended): The composition of claim 23, wherein the adrenergic bronchodilator component is a beta₂-adrenergic bronchodilator.

Claim 25. (Currently Amended): The composition of claim 23, wherein the histamine receptor antagonist component is a histamine receptor ~~H₁-receptor~~ H₁-receptor antagonist.

Claim 26. (Canceled)

Claim 27. (Currently Amended): The composition of claim 23, wherein the leukotriene receptor antagonist component is selected from the group consisting of:
montelukast sodium, zafirlukast sodium, and combinations thereof.

Claim 28. (Canceled)

Claim 29. (Canceled)

Claim 30. (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is cetirizine hydrochloride;
- (b) The leukotriene receptor antagonist is montelukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 31. (Canceled)

Claim 32. (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is fexofenadine;
- (b) The leukotriene receptor antagonist is montelukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 33. (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is cetirizine hydrochloride;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 34. (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is loratadine;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 35. (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is fexofenadine;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 36. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 23.

Claim 37. (Withdrawn): The method of claim 36, wherein the amount of the histamine receptor antagonist in the composition is between about 2.5 mg and about 180 mg.

Claim 38. (Withdrawn): The method of claim 36, wherein the amount of the leukotriene receptor antagonist in the composition is between about 4 mg and about 20 mg.

Claim 39. (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is between about 4 mg and about 8 mg.

Claim 40. (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 2 mg.

Claim 41. (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 0.1mg/kg of the patient's body weight.

Claim 42. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 29.

Claim 43. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 30.

Claim 44. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 31.

Claim 45. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 32.

Claim 46. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 33.

Claim 47. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 34.

Claim 48. (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 35.

Claim 49. (Currently Amended): A composition for the treatment of asthma, the composition comprising:

a first receptor antagonist component and a second receptor antagonist component, said first and second receptor ~~antagonists~~ antagonist components being independently selected from

the group consisting of leukotriene receptor antagonists, histamine receptor antagonists, and combinations thereof; and

an adrenergic bronchodilator component, the adrenergic bronchodilator component including an immediate release ~~portion~~ form and an extended release ~~portion~~ form, wherein said immediate release form is present in an amount substantially equal to said extended release form.

Claim 50. (Currently Amended): The composition of Claim 49, wherein said adrenergic bronchodilator component is a beta₂-adrenergic bronchodilator.

Claim 51. (Previously Presented): The composition of Claim 50, wherein said beta₂-adrenergic bronchodilator is albuterol.

Claim 52. (Previously Presented): The composition of Claim 49, wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast sodium, zafirlukast sodium, and combinations thereof.

Claim 53. (Previously Presented): The composition of Claim 49, wherein said histamine receptor antagonist is a histamine H₁-receptor antagonist.

Claim 54. (Previously Presented): The composition of Claim 53, wherein said histamine H₁-receptor antagonist is selected from the group consisting of cetirizine hydrochloride, loratadine, fexofenadine, and combinations thereof.

Claim 55. (Currently Amended): A composition for treatment of asthma, the composition comprising:

a first receptor antagonist component comprising a leukotriene receptor antagonist;
a second receptor antagonist component comprising a histamine receptor antagonist; and
an adrenergic bronchodilator component, the adrenergic bronchodilator component including an immediate release ~~portion~~ form and an extended release ~~portion~~ form, wherein said immediate release form is present in an amount substantially equal to said extended release form.

Claim 56. (Currently Amended): The composition of Claim 55, wherein said adrenergic bronchodilator component is a beta₂-adrenergic bronchodilator.

Claim 57. (Previously Presented): The composition of Claim 56, wherein said beta₂-adrenergic bronchodilator is albuterol.

Claim 58. (Previously Presented): The composition of Claim 55, wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast sodium, zafirlukast sodium, and combinations thereof.

Claim 59. (Currently Amended): The composition of Claim 55, wherein said histamine receptor antagonist is a histamine ~~H1-receptor~~ H₁-receptor antagonist.

Claim 60. (Currently Amended): The composition of Claim 59, wherein said histamine ~~H1-receptor~~ H₁-receptor antagonist is selected from the group consisting of cetirizine hydrochloride, loratadine, fexofenadine, and combinations thereof.

Claim 61. (Currently Amended): A composition for the treatment of asthma, the composition comprising:

a montelukast sodium component;

an antihistamine component selected from the group consisting of cetirizine, loratadine, fexofenadine, and combinations thereof; and

an adrenergic bronchodilator component, the adrenergic bronchodilator component including an immediate release ~~portion~~ form and an extended release ~~portion~~ form, wherein said immediate release form is present in an amount substantially equal to said extended release form.

Claim 62. (Currently Amended): The composition of Claim 61, wherein said adrenergic bronchodilator component is albuterol.